Akebia Therapeutics R&D Day: Vafseo Growth Plan, Praliciguat Phase 2, New Kidney Pipeline Targets [Yahoo! Finance]
Akebia Therapeutics, Inc. (AKBA)
Last akebia therapeutics, inc. earnings: 3/10 07:49 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.akebia.com/investor-relations
Company Research
Source: Yahoo! Finance
revenue in 2025, patient access rising from ~40,000 to ~290,000, improved adherence to ~87%, and planned evidence readouts (JASN publication, VOCAL end-2026, VOICE early-2027) to support broader uptake. Praliciguat (sGC stimulator) showed preclinical anti-fibrotic effects and a reanalysis suggesting ~20–25% UACR reduction, and Akebia has launched a randomized Phase 2 in biopsy-confirmed FSGS (up to 60 patients, 24 weeks) with UPCR change and partial remission as primary endpoints. New pipeline milestones : AKB-097 (abribafisp), a tissue-targeted complement inhibitor with favorable Phase 1 safety and a 450 mg weekly SC dose to limit systemic complement suppression, is slated for a Phase 2 rare kidney disease basket trial in 2H 2026; AKB-9090 (HIF-PHI) has begun Phase 1 (New Zealand) with Phase 1 data expected before end-2026 and a planned Phase 2 in cardiac surgery-associated AKI. Interested in Akebia Therapeutics, Inc.? Here are five stocks we like better. Akebia Therapeutics
Show less
Read more
Impact Snapshot
Event Time:
AKBA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKBA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKBA alerts
High impacting Akebia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AKBA
News
- Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D Day Transcript [Seeking Alpha]Seeking Alpha
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of DirectorsGlobeNewswire
- Is Akebia Therapeutics (AKBA) One of the Best Penny Stocks to Buy [Yahoo! Finance]Yahoo! Finance
- Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026 [Yahoo! Finance]Yahoo! Finance
AKBA
Earnings
- 2/26/26 - Miss
AKBA
Sec Filings
- 4/1/26 - Form 8-K
- 3/26/26 - Form SCHEDULE
- 3/5/26 - Form 4
- AKBA's page on the SEC website